Semaglutide or tirzepatide? Let's cut to it — both are real, both are prescriptions, and one tended to win on weight loss.
The short version
Both are legit, approved weight-loss drugs. The headline difference: tirzepatide hits two gut hormones, semaglutide hits one — and in trials, tirzepatide tended to drive more weight loss. But which fits *you* is a doctor's decision, not a leaderboard. And both are prescription-only for a reason.
The head-to-head
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Brand names | Wegovy, Ozempic | Zepbound, Mounjaro |
| How it works | One target (GLP-1) | Two targets (GLP-1 + GIP) |
| Weight loss in trials | Strong | Tended to be greater head-to-head |
| Status | Approved, prescription-only | Approved, prescription-only |
Semaglutide: the one that started the wave
Semaglutide is the GLP-1 that made this whole category famous — Ozempic for diabetes, Wegovy for weight. It mimics a gut hormone that curbs appetite, and the weight-loss evidence is strong. It's a real, approved medicine. It's also prescription-only, with side effects, and it's not something you self-source off a website.
Tirzepatide: the double-target one
Tirzepatide is the newer one, and it does something semaglutide doesn't — it hits two hormone systems (GLP-1 *and* GIP) instead of one. In head-to-head trials, that tended to translate into more weight loss on average. Impressive on paper. But 'more weight loss' isn't a free win — more effect can mean more side effects for some people, and that trade-off is exactly what a doctor is for.
What's next: retatrutide
You'll hear buzz about retatrutide — a next-gen drug hitting *three* targets, showing big numbers in trials. Keep it in perspective: it's still in clinical trials, not approved, not on shelves. Promising, not proven. Anyone selling it to you right now is selling you something they shouldn't.
What's true
- Both are approved, prescription-only, and genuinely drive weight loss
- Tirzepatide hits two targets and tended to more weight loss in trials
- A doctor decides which one (if either) fits you
What's a myth
- 'Tirzepatide is always better' — more effect isn't automatically better for you
- 'You can safely buy a research version to save money' — you can't verify it
- 'Retatrutide is available now' — it's still in trials
The honest verdict
Both are the real deal. Tirzepatide tended to edge out semaglutide on weight loss in trials thanks to its dual-target design — but the right pick depends on your side effects, cost, and health, and that's a doctor's call. Retatrutide is one to watch, not to buy. And grey-market versions of any of them are a hard skip.
What this does not mean
- This doesn't mean tirzepatide is the right choice for everyone — 'more weight loss on average' isn't a personal prescription.
- This doesn't mean you can safely buy a cheaper 'research' version — you can't verify grey-market vials.
- This is general info, not medical advice — a doctor decides which drug, if any, fits you.